Hennion & Walsh Asset Management, Inc. Intellia Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 153,150 shares of NTLA stock, worth $3.81 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
153,150
Previous 146,466
4.56%
Holding current value
$3.81 Million
Previous $1.18 Million
21.59%
% of portfolio
0.06%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding NTLA
# of Institutions
334Shares Held
97MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$324 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$270 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$239 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$103 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$101 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.89B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...